# Opus Genetics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Opus Genetics, Inc.). ## Overview Opus Genetics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and other ophthalmic disorders. Its pipeline includes AAV-based gene therapy programs, a small-molecule ophthalmic candidate, and a licensed eye-drop product that generates royalty revenue through a partner. ## Products & services • AAV gene therapies for inherited retinal diseases • LCA5 gene therapy programs • BEST1 and RHO ophthalmic gene therapy programs • Phentolamine Ophthalmic Solution 0.75% (RYZUMVI®) • APX3330 for non-proliferative diabetic retinopathy • License and collaboration agreements - **Gene therapy programs** (0%) — AAV-based therapies targeting inherited retinal disease mutations and other ophthalmic disorders. - **Licensed ophthalmic product** (15%) — Phentolamine Ophthalmic Solution 0.75% marketed by a partner and generating royalties. - **Small-molecule ophthalmology candidate** (0%) — APX3330, a Ref-1 inhibitor being developed for diabetic retinopathy. - **License and collaboration revenue** (85%) — Milestones, reimbursements, and other non-product revenue from partners. - AAV gene therapies for inherited retinal diseases - LCA5 gene therapy programs - BEST1 and RHO ophthalmic gene therapy programs - Phentolamine Ophthalmic Solution 0.75% (RYZUMVI®) - APX3330 for non-proliferative diabetic retinopathy - License and collaboration agreements ## Customers Opus primarily serves patients with inherited retinal diseases and other serious eye disorders through its development pipeline, while its commercial exposure comes indirectly through partners that market licensed products. Revenue today is tied mainly to collaboration counterparties and royalty-bearing arrangements rather than direct end-customer sales. The company’s future commercial customers would include retina specialists, ophthalmologists, and treatment centers if its pipeline products reach approval. - **Rare disease patients and caregivers** (primary) — Patients with IRDs, LCA, bestrophinopathy, or retinitis pigmentosa who would receive approved gene therapies or ophthalmic treatments. - **Pharmaceutical and biotech partners** (primary) — Licensees and collaborators that fund development, pay milestones, or commercialize partnered assets such as RYZUMVI®. - **Eye care specialists** (secondary) — Retina specialists and ophthalmologists who would diagnose, refer, and prescribe if pipeline assets are approved. - **Payers and health systems** (secondary) — Insurers and healthcare systems that would reimburse high-value ophthalmic therapies after approval. - Patients with inherited retinal diseases are the ultimate end users - Retina specialists and ophthalmologists would prescribe approved therapies - Partners and licensees pay milestones, reimbursements, and royalties - Commercial demand depends on rare-disease diagnosis and specialist referral - Future product sales would target ophthalmic treatment centers ## Geography Opus is headquartered in the United States and operates as a U.S. biopharmaceutical company, with development and partnering activity centered on ophthalmology programs. Its addressable market is global because inherited retinal diseases occur across U.S. and ex-U.S. patient populations, and the company’s licensing and commercialization opportunities can extend beyond the United States. - Headquartered in the United States - Clinical development and corporate functions are U.S.-based - IRD patient populations exist in both U.S. and ex-U.S. markets - Future partnering and commercialization can extend internationally ## Strategy Opus is focused on advancing its gene therapy pipeline for inherited retinal diseases while maintaining partnered and licensed assets that can generate non-dilutive revenue. It also seeks collaborations, out-licensing, and potential in-licensing to broaden its ophthalmology portfolio and support development. - **Advance gene therapy pipeline** (medium-term) — Clinical progress is the main path to value creation in rare ophthalmic diseases. - **Partner non-core assets** (short-term) — Collaborations can reduce funding needs and keep programs moving without full internal commercialization. - **Expand ophthalmology portfolio** (medium-term) — Additional assets can diversify scientific risk and broaden the addressable market. - **Monetize partnered products** (short-term) — Royalties and milestones can provide non-dilutive support while pipeline assets mature. - Advance gene therapy programs for IRDs - Seek partners for APX3330 and other late-stage assets - Use licensing and collaborations to fund development - Expand the ophthalmology pipeline through in-licensing or acquisition - Preserve optionality across rare-disease and broader eye-care markets ## Risks Opus faces the typical risks of a clinical-stage biotech company: uncertain clinical outcomes, regulatory approval risk, and dependence on intellectual property protection. It also relies on collaborators, external funding, and successful manufacturing scale-up for gene therapy programs, any of which can delay development or reduce future revenue. - **Clinical development failure or delay** [critical] — The pipeline is based on novel gene therapy and ophthalmic mechanisms with uncertain trial outcomes and timelines. - **Manufacturing and scale-up risk** [high] — Gene therapies require specialized production capacity and quality control that can constrain trial execution and launch readiness. - **Intellectual property protection risk** [high] — The business depends on patents, licenses, and trademarks to protect product candidates and partner value. - **Collaborator dependence** [high] — Milestones, reimbursements, and commercialization may depend on third parties that can change priorities or funding. - **Financing and dilution risk** [high] — As a clinical-stage company, ongoing development requires external capital before product revenue is established. - Clinical trials may fail or take longer than expected - Gene therapy manufacturing scale-up is technically difficult - Patent and trademark protection may be challenged - Collaborators may underfund or deprioritize programs - Future revenue depends on regulatory approval and commercialization ## Accounting The most important accounting issue is revenue recognition for license and collaboration arrangements, including one-time payments, milestones, reimbursements, and royalties. Fair value changes in warrant and derivative liabilities can also create volatility in reported results, while acquisition-related intangible assets and contingent obligations require judgment and may affect future earnings. - **License and collaboration revenue recognition** — license agreements, Viatris-related revenue - **Fair value of warrant and derivative liabilities** — reported net loss volatility - **Acquisition accounting and contingent consideration** — balance sheet and future earnings - **R&D expense estimation** — research and development expense - License and collaboration revenue depends on milestone and reimbursement timing - Royalties from partnered products affect revenue recognition patterns - Warrant and derivative liabilities are remeasured at fair value - Acquisition-related intangibles and contingent obligations require estimates - R&D and clinical-stage costs drive period-to-period comparability --- *Last updated: 2026-04-29T04:44:15.843347+00:00*